Camp4 Therapeutics vs Korro Bio
CAMP and KRRO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CAMP and KRRO compare
Camp4 Therapeutics is the larger company, worth 1.2 times as much as Korro Bio ($257M against $211M).
Camp4 Therapeutics grew revenue faster over the last twelve months (39.9% versus −82.5% for Korro Bio).
Camp4 Therapeutics keeps more of each dollar of sales as profit, with a net margin of −2276% compared with −8214% at Korro Bio.
Camp4 Therapeutics scores higher on the StockData Score (6 against 5 for Korro Bio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CAMP | KRRO |
|---|---|---|
| Size and price | ||
| Market cap | $257M | $211M |
| Share price | $4.09 | $14.31 |
| Change, 1 year | −0.97% | −56.4% |
| Change, 5 years | −98.2% | −95.2% |
| Beta (5Y) | 2.72 | 2.09 |
| Employees | 48 | 58 |
| StockData Score | ||
| Total score | 6 (better) | 5 |
| Valuation score | 0 | 0 |
| Growth score | 1 (better) | 0 |
| Performance score | 0 | 0 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 48.2× (better) | 163× |
| P/B | 2.4× | – |
| FCF yield | −10.3% (better) | −30.3% |
| Fair value | $2.51 | – |
| Margin of safety | −63.0% | – |
| Growth | ||
| Revenue growth (TTM) | 39.9% (better) | −82.5% |
| Revenue growth, 5Y average | – | −29.6% |
| Profitability | ||
| Operating margin | −1001% (better) | −8467% |
| Net margin | −2276% (better) | −8214% |
| FCF margin | −496% (better) | −4944% |
| Return on equity | −146% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Current ratio | 6.42 | 7.30 (better) |
| Altman Z-score | 1.52 (better) | −3.71 |
| Piotroski F-score | 4 (better) | 2 |
| Dividends and buybacks | ||
| Dividend yield | 0.00% | – |
| Years of dividend growth | 0 | – |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 66.5% | 102% |
| Held by insiders | 21.7% | 27.5% |
| Insider net buying, 12 months | −$2.4M | $16.0M (better) |
| Short interest, % of float | 6.6% | 16.4% |
Go deeper
- CAMP stock overview
- CAMP income statement
- CAMP valuation and score
- KRRO stock overview
- KRRO income statement
- KRRO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.